Fulcrum therapeutics posts q1 loss per share of $0.81

Fulcrum therapeutics reports recent business highlights and first quarter 2020 financial results.fulcrum therapeutics - as of march 31, 2020, cash, cash equivalents, marketable securities were $81.2 million, as compared to $96.7 million as of dec 31, 2019.fulcrum therapeutics inc qtrly loss per share $0.81.fulcrum therapeutics inc - expects existing cash will be sufficient to enable it to fund its operating expenses into q3.
FULC Ratings Summary
FULC Quant Ranking